DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Daratumumab is an investigational drug.
There have been 123 clinical trials for Daratumumab. The most recent clinical trial was a Phase 1 trial, which was initiated on January 15th 2019.
The most common disease conditions in clinical trials are Multiple Myeloma, Neoplasms, Plasma Cell, and Leukemia. The leading clinical trial sponsors are Janssen Research & Development, LLC, Janssen, LP, and National Cancer Institute (NCI).
There are eight US patents protecting this investigational drug and one hundred and ninety-six international patents.
Recent Clinical Trials for Daratumumab
|Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma||Janssen, LP||Phase 2|
|Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma||Takeda||Phase 2|
|Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma||Emory University||Phase 2|
Top disease conditions for Daratumumab
Top clinical trial sponsors for Daratumumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Daratumumab||Start Trial||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||Start Trial|
|Daratumumab||Start Trial||Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts||Advenchen Pharmaceuticals, LLC (Moorpark, CA)||Start Trial|
|Daratumumab||Start Trial||Blocking CD38 using anti-CD38 F(ab')2 to protect NK cells||The United States of America, as represented by the Secretary, Department of Health and Human Services (Washington, DC) Janssen Biotech, Inc. (Spring House, PA)||Start Trial|
|Daratumumab||Start Trial||Treating myelomas||Mayo Foundation for Medical Education and Research (Rochester, MN)||Start Trial|
|Daratumumab||Start Trial||Mesalamine for the treatment of cancer||Cipla Limited (Mumbai, IN)||Start Trial|
|Daratumumab||Start Trial||Constructs having a SIRP-.alpha. domain or variant thereof||ALX ONCOLOGY INC. (Burlingame, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Daratumumab||European Patent Office||2954056||2033-02-08||Start Trial|
|Daratumumab||Hong Kong||1218930||2033-02-08||Start Trial|
|Daratumumab||World Intellectual Property Organization (WIPO)||2014124326||2033-02-08||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|